How Biotech Cos. Can Utilize Synthetic Royalty Financing
Following the capital markets boom fueled by the Fed's accommodating monetary policy in 2020 and 2021, the biotech sector suffered nearly a 50% drop over a 12-month period from February 2021...To view the full article, register now.
Already a subscriber? Click here to view full article